GlassScriptPhysician profile
Fiona Blair
NPI 1558342352
$1,150.86
in general payments reported to CMS, 2019-2025
11 companies · $42.25 in 2025
The $42.25 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $126 · 2021: $110 · 2022: $172 · 2023: $139 · 2024: $76.34 · 2025: $42.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $563.51 | 2019-2024 | |
| Baxter Healthcare | $171.72 | 2022 | |
| Sanofi Pasteur INC. | $95.12 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $78.49 | 2020-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $70.82 | 2019-2021 | |
| Glaxosmithkline, LLC. | $43.34 | 2020-2023 | Bexsero, Rotarix, Menveo |
| Sanofi-Aventis U.S. LLC | $34.85 | 2024-2025 | |
| Adlon Therapeutics L.P. | $26.86 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $23.82 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $22.64 | 2023 | Flumist Quadrivalent |
| Novo Nordisk INC | $19.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.